Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TMS CoTSE:4891 +1.03%32 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4891 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, TMS Co ranks worse than 106157.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. TMS Co's EBITDA for the
three
months ended in Dec. 2025 was 円0.00 Mil. TMS Co's Revenue for the
three
months ended in Dec. 2025 was 円0.00 Mil. Therefore, TMS Co's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TMS Co EBITDA Margin % Related Terms
TMS Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TMS Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4891 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, TMS Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMS Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TMS Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TMS Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMS Co (TSE:4891) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TMS Co and its competitors. Over the past decade, TMS Co's EBITDA Margin % has ranged from 58.38 to 58.38. According to the industry distribution chart, TMS Co ranks #999999 out of 942 companies in the Biotechnology industry.
Is TMS Co's EBITDA Margin % too high?
TMS Co's current EBITDA Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 58.38 to a high of 58.38. Based on the distribution chart, TMS Co ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TMS Co has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TMS Co ranks #999999 out of 942 companies for EBITDA Margin %. This places TMS Co in the lower half of its industry. Historically, TMS Co's own EBITDA Margin % has ranged from 58.38 to 58.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TMS Co and its competitors. TMS Co's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. TMS Co's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TMS Co (TSE:4891), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
32GF Score
Get the complete analysis for TSE:4891
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4891 has been successfully added to your 
